CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...

Novartis CEO Vas Narasimhan has expressed concern over the United States' withdrawal from the World Health Organization, highlighting potential impacts on global health initiatives. These programmes, ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals ...

FRANKFURT, Jan 31 (Reuters) - The American CEO of Swiss drugmaker Novartis on Friday warned that ... to get the medicines that they need," CEO Vas Narasimhan said at a news conference after ...

As Trump appointee and vaccine skeptic RFK Jr. looks toward Washington, Novartis (NVS) CEO Vas Narasimhan is concerned about ...

Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's ...

Reports Q4 revenue $13.2B vs. $11.4B last year. Vas Narasimhan, CEO of Novartis (NVS), said: “In our first full year as a pure-play innovative ...

Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued st ...

It also saw increased use in China and Japan for hypertension management. In an interview with CNBC, Novartis CEO Vas Narasimhan downplayed concerns about Entresto’s U.S. patent expiration ...